Table 3

Five-year probabilities of survival, PFS, and probability of achieving CCyR according to the different constituents of the definitions of failure, suboptimal response, and warning

N*Survival, %PFS, %Probability of CCyR, %
At diagnosis     
    Sokal risk group  P = .02 P = .02 P = .0004 
        Low and intermediate 156 93.5 (CI, 88.4-96.4) 91.3 (CI, 87.9-93.8) 84.0 (CI, 80.2-87.2) 
        High 68 72.4 (CI, 50.5-87.1) 69.6 (CI, 61.3-76.8) 61.8 (CI, 55.8-67.5) 
    Karyotype  P = .03 P = .003 P = .37 
        Ph chromosome only 209 88.4 (CI, 81.2-93.1) 85.4 (CI, 81.0-88.9) 77.4 (CI, 74.3-80.2) 
        ACAs in Ph+ cells 15 42.9 (CI, 14.8-76.5) 35.7 (CI, 13.4-66.6) 71.4 (CI, 54.1-84.1) 
3 months     
    Lack of hematologic response  P = .003 P = .002 P = .0003 
        Yes 8 60.2 (CI, 40.5-77.0) 56.2 (CI, 38.9-72.1) 0 
        No 216 93.2 (CI, 84.8-97.1) 84.6 (CI, 80.3-88.1) 80.1 (CI, 75.5-84.1 
    Lack of CHR  P = .003 P = .002 P = .0003 
        Yes 8 60.2 (CI, 40.5-77.0) 56.2 (CI, 38.9-72.1) 0 
        No 216 93.2 (CI, 84.8-97.1) 84.6 (CI, 80.3-88.1) 80.1 (CI, 75.5-84.1) 
6 months     
    CHR  P = .0001 P = .0002 P = .0001 
        Yes 210 95.1 (CI, 89.5-97.8) 86.7 (CI, 83.3-89.5) 82.4 (CI, 80.1-84.5) 
        No 9 59.6 (CI, 38.2-77.8) 49.4 (CI, 31.2-67.7) 0 
    Cytogenetic response (≤95 % Ph+)  P = .04 P = .007 P < .0001 
        Yes 185 94.9 (CI, 92.3-96.7) 87.1 (CI, 85.0-88.9) 90.3 (CI, 82.8-94.7) 
        No 34 84.6 (CI, 72.5-92.0) 72.8 (CI, 64.4-79.9) 17.6 (CI, 15.0-20.5) 
    MCyR (≤35% Ph+)  P = .09 P = .0007 P < .0001 
        Yes 157 93.2 (CI, 83.7-97.3) 91.5 (CI, 88.1-94.0) 95.5 (CI, 93.9-96.7) 
        No 62 74.2 (CI, 58.8-85.3) 70.4 (CI, 62.1-77.6) 37.1 (CI, 31.4-43.1) 
12 months     
    MCyR (≤35% Ph+)  P = .1 P = .003 P < .0001 
        Yes 169 95.1 (CI, 90.6-97.5) 90.0 (CI, 86.9-92.4) 95.3 (CI, 94.2-96.2) 
        No 46 86.7 (CI, 75.5-93.2) 76.3 (CI, 67.7-83.2) 23.9 (CI, 20.2-28.0) 
    CCyR (0% Ph+)  P = .009 P = .0006 P < .0001 
        Yes 127 98.4 (CI, 95.9-99.4) 96.2 (CI, 94.3-97.5) 100 
        No 88 86.0(CI, 79.1-90.9) 74.4 (CI, 70.3-78.1) 48.2 (CI, 42.4-54.1) 
    MMR  P = .8 P = .3  
        Yes 32 96.4 (CI, 85.2-99.2) 94.4 (CI, 86.5-97.8)  
        No 183 93.4 (CI, 88.3-96.4) 85.3 (CI, 81.7-88.3)  
18 months     
    CCyR (0% Ph+)  P = .03 P = .002 P < .0001 
        Yes 132 98.5 (CI, 93.9-99.6) 97.1 (CI, 94.1-98.6) 100 
        No 65 87.6 (CI, 80.5-92.3) 76.5 (CI, 70.8-81.4) 36.9 (CI, 30.4-44.0) 
    MMR  P = .96 P = .39  
        Yes 41 95.6 (CI, 89.8-98.2) 94.5 (CI, 89.2-97.3)  
        No 156 94.5 (CI, 85.4-98.1) 87.5 (CI, 80.2-94.2)  
Any time during follow-up     
    Loss of CHR† 18 5.2 (P = .01; CI, 1.4-19.6) 8.8 (P < .0001; CI, 3.6-21.5) NA 
    Loss of CCyR† 17 3.2 (P = .04; CI,1.1-15.4) 6.95 (P = .001; CI, 2.2-21.7) NA 
    Highly resistant TK mutation 2 0.49 (P = .8; CI 0.001-1003) 0.49 (P = .5; CI, 0.02-308) NA 
    Acquisition of ACA in Ph+ cells† 16 4.0 (P = .05; CI, 1.02-23.6) 5.5 (P = .03; CI, 1.3-17.7) NA 
    Loss of MMR‡ 10 0.04 (P = .6 CI, 0.0003-21675) 0.04 (P = .3; CI, 0.0005-15654) NA 
    ACA in Ph− cells 8 2.5 (P = .6; CI, 0.2-65.1) 1.8 (P = .8; CI, 0.4-35.7) NA 
    TK mutation† 12 4.4 (P = .1; CI, 0.8-14.7) 3.0 (P = .03; CI, 1.2-11.1) NA 
N*Survival, %PFS, %Probability of CCyR, %
At diagnosis     
    Sokal risk group  P = .02 P = .02 P = .0004 
        Low and intermediate 156 93.5 (CI, 88.4-96.4) 91.3 (CI, 87.9-93.8) 84.0 (CI, 80.2-87.2) 
        High 68 72.4 (CI, 50.5-87.1) 69.6 (CI, 61.3-76.8) 61.8 (CI, 55.8-67.5) 
    Karyotype  P = .03 P = .003 P = .37 
        Ph chromosome only 209 88.4 (CI, 81.2-93.1) 85.4 (CI, 81.0-88.9) 77.4 (CI, 74.3-80.2) 
        ACAs in Ph+ cells 15 42.9 (CI, 14.8-76.5) 35.7 (CI, 13.4-66.6) 71.4 (CI, 54.1-84.1) 
3 months     
    Lack of hematologic response  P = .003 P = .002 P = .0003 
        Yes 8 60.2 (CI, 40.5-77.0) 56.2 (CI, 38.9-72.1) 0 
        No 216 93.2 (CI, 84.8-97.1) 84.6 (CI, 80.3-88.1) 80.1 (CI, 75.5-84.1 
    Lack of CHR  P = .003 P = .002 P = .0003 
        Yes 8 60.2 (CI, 40.5-77.0) 56.2 (CI, 38.9-72.1) 0 
        No 216 93.2 (CI, 84.8-97.1) 84.6 (CI, 80.3-88.1) 80.1 (CI, 75.5-84.1) 
6 months     
    CHR  P = .0001 P = .0002 P = .0001 
        Yes 210 95.1 (CI, 89.5-97.8) 86.7 (CI, 83.3-89.5) 82.4 (CI, 80.1-84.5) 
        No 9 59.6 (CI, 38.2-77.8) 49.4 (CI, 31.2-67.7) 0 
    Cytogenetic response (≤95 % Ph+)  P = .04 P = .007 P < .0001 
        Yes 185 94.9 (CI, 92.3-96.7) 87.1 (CI, 85.0-88.9) 90.3 (CI, 82.8-94.7) 
        No 34 84.6 (CI, 72.5-92.0) 72.8 (CI, 64.4-79.9) 17.6 (CI, 15.0-20.5) 
    MCyR (≤35% Ph+)  P = .09 P = .0007 P < .0001 
        Yes 157 93.2 (CI, 83.7-97.3) 91.5 (CI, 88.1-94.0) 95.5 (CI, 93.9-96.7) 
        No 62 74.2 (CI, 58.8-85.3) 70.4 (CI, 62.1-77.6) 37.1 (CI, 31.4-43.1) 
12 months     
    MCyR (≤35% Ph+)  P = .1 P = .003 P < .0001 
        Yes 169 95.1 (CI, 90.6-97.5) 90.0 (CI, 86.9-92.4) 95.3 (CI, 94.2-96.2) 
        No 46 86.7 (CI, 75.5-93.2) 76.3 (CI, 67.7-83.2) 23.9 (CI, 20.2-28.0) 
    CCyR (0% Ph+)  P = .009 P = .0006 P < .0001 
        Yes 127 98.4 (CI, 95.9-99.4) 96.2 (CI, 94.3-97.5) 100 
        No 88 86.0(CI, 79.1-90.9) 74.4 (CI, 70.3-78.1) 48.2 (CI, 42.4-54.1) 
    MMR  P = .8 P = .3  
        Yes 32 96.4 (CI, 85.2-99.2) 94.4 (CI, 86.5-97.8)  
        No 183 93.4 (CI, 88.3-96.4) 85.3 (CI, 81.7-88.3)  
18 months     
    CCyR (0% Ph+)  P = .03 P = .002 P < .0001 
        Yes 132 98.5 (CI, 93.9-99.6) 97.1 (CI, 94.1-98.6) 100 
        No 65 87.6 (CI, 80.5-92.3) 76.5 (CI, 70.8-81.4) 36.9 (CI, 30.4-44.0) 
    MMR  P = .96 P = .39  
        Yes 41 95.6 (CI, 89.8-98.2) 94.5 (CI, 89.2-97.3)  
        No 156 94.5 (CI, 85.4-98.1) 87.5 (CI, 80.2-94.2)  
Any time during follow-up     
    Loss of CHR† 18 5.2 (P = .01; CI, 1.4-19.6) 8.8 (P < .0001; CI, 3.6-21.5) NA 
    Loss of CCyR† 17 3.2 (P = .04; CI,1.1-15.4) 6.95 (P = .001; CI, 2.2-21.7) NA 
    Highly resistant TK mutation 2 0.49 (P = .8; CI 0.001-1003) 0.49 (P = .5; CI, 0.02-308) NA 
    Acquisition of ACA in Ph+ cells† 16 4.0 (P = .05; CI, 1.02-23.6) 5.5 (P = .03; CI, 1.3-17.7) NA 
    Loss of MMR‡ 10 0.04 (P = .6 CI, 0.0003-21675) 0.04 (P = .3; CI, 0.0005-15654) NA 
    ACA in Ph− cells 8 2.5 (P = .6; CI, 0.2-65.1) 1.8 (P = .8; CI, 0.4-35.7) NA 
    TK mutation† 12 4.4 (P = .1; CI, 0.8-14.7) 3.0 (P = .03; CI, 1.2-11.1) NA 

NA indicates not applicable.

*

N represents the number of patients with the indicated characteristic.

†

Before accelerated or blastic phase.

‡

A very similar result was obtained when only patients who had achieved MMR were analyzed.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal